Global Outsourcing by Virtual Companies
The factors to consider in outsourcing by a virtual pharmaceutical company were addressed by Zhengming Chen, senior director of chemistry and CMC of Dov Pharmaceutical in his presentation, “Optimized R&D Outsourcing Business Model: From PreClinical to Development: A Case Study,” at Interphex.
Dov Pharmaceutical is a biopharmaceutical company focused on the discovery, acquisition, and development of novel drug candidates for treating disorders of the central nervous system. Dov operates as a virtual company by focusing on discovery of drug candidates and using outsourcing partners to fill its needs in the drug-development process in areas such as lead optimization and medicinal chemistry, process development and manufacturing of active pharmaceutical ingredients, and drug product and clinical packaging.
Even as small company, Chen pointed out that Dov Pharmaceutical uses a global outsourcing strategy and considers and uses partners based in the United States, Europe, and Asia. Globalization of the pharmaceutial industry is often considered in the realm of Big Pharma and the optimization of its development activities and manufacturing networks, but it is also an important part of doing business for the small players. As Big Pharma continues to struggle with product innovation and making its pipeline fertile, meeting the demands of the global virtual pharmaceutical company is an important paradigm in outsourcing.
Share your perspectives in meeting the outsourcing needs by virtual companies and leave a comment below.
Ladies and Gentlemen,
It is our pleasure to introduce the Clinical Research Scientific Advisory Committee which has been established and is managed by the Clinical Research Foundation EEU.
The Clinical Research Scientific Advisory Committee is an alliance of the most experienced and honored medical and clinical research professionals: active key opinion leaders in various clinical indications from the Eastern European Area.
Based on extended experience and expertise in all indication fields and in the development of Clinical and Medical Research processes, the principal members of the Clinical Research Scientific Advisory Committee believe in beginning a New Clinical Research Development Initiative in support of Pharma Industry and Research Institutions.
The intent of the initiative is to improve and continuously reinforce the quality and effectiveness of the processes on preparation and professional implementation of clinical research in the Eastern EU countries.
In light of all the above, the Clinical Research Scientific Advisory Committee is offering its capability in expertise and scientific authority in the EEU area to the pharma industry, research institutions, governmental organizations, etc. by developing an active partnership.
Being connected with a big number of active clinical and medical research KOLs, especially in the Eastern European Area, we have been successful to organize the specific formation (Clinical Research Scientific Advisory Committee) of most experienced and honored specialists covering almost all indication fields of clinical research expertise.
It is also to be mentioned that into our sub-committees we have included different other experts covering questions of Ethics and Regulatory Affairs, finance and legal affairs, clinical operations, etc.
The main goal of our activities is to direct and trustfully collaborate with pharma companies in respect of the efficient and effective clinical trial implementation in the for clinical research very important part of Europe – Eastern Europe (mainly Baltic States, Russia, Ukraine and Belarus).
I would like to make some kind of short scenario examples of very general expertise points we are providing to our partners:
1) Evaluation of a program/protocol/synopsis, recommendation on the indication/area specific requirements (Medical, Ethical/Regulatory, etc)
2) Evaluation and recommendation on country/sites number/expected patients enrolment/timelines for each specific indication/protocol in the area above
3) Area/country specific Lead PI/KOL project governance functionality during conduct of a clinical protocol/program,
4) Expert level consultations with National Ethics/Regulatory bodies and support at any stage of trials implementation, etc.
5) Recommendations on Institution/Investigators contracts negotiation; centralized Institution/Investigator payments handling, while contractually guaranteed patient recruitment within agreed demanding real timelines
6) We consider any other specific partnership tasks
If you should have any interest in collaboration with the Clinical and Medical Research Key Opinion Leaders from the EEU area through the Clinical Research Scientific Advisory Committee, please obtain further information from our web page of the Clinical Research Foundation EEU – http://www.crfound-eeu.com .
Sincerely Yours,
Dainis Krievins, MD, PhD
Board Executive Director
Clinical Research Foundation EEU
Tel: 37129450000